| *Sponsored
(NNVC) Update: Today's NYSE American Profile Jumps Bell With Green Move (Huge Announcement)
February 12th Greetings, Friend!
(NYSE American: NNVC) is starting strong with an early green push.
Part of the reason could be because of this major announcement yesterday. Take a look:
NanoViricides Drug Can Fight Bird Flu Pand-em-ic; H-5-N-1 Vi-rus Cannot Escape
NanoViricides, Inc. (NYSE American:NNVC) (the "Company") declared today that it is ready to fight the bird flu with its revolutionary broad-spectrum antiviral drug NV-387, a drug that the Bird Flu vi-rus H-5-N-1 likely cannot escape despite its ability to mutate rapidly with genomic changes.
...
"Vaccines are not the right response for fast-moving vi-rus-es such as S-C-2 or H-5-N-1, because vaccine deployment is at least 12 to 15 months behind the vi-rus, when the vi-rus has already moved on," commented Anil R. Diwan, PhD, adding, "We must learn from past pand-em-ics and past mistakes. We believe that the iconoclastic Trump 2.0 administration will heed these lessons."
...
Read the full article here.
Remember. This is a low float idea with fewer than 14Mn shares in its float. That means volatility potential could be explosive.
Read my initial report below and consider (NYSE American: NNVC) for your radar today. -----
It's been a few days, so let me get you all caught up.
My last profile, an under-the-radar Nasdaq idea, caught the breakout bug in the short term.
Surging from a previous night's after-hours close of $6.86+ on 2/6, that profile ballooned to a high of $8.86 one day later.
Popping almost $2.00, the run resulted in a blast of approx. 29%.
Solid, but let's turn our focus to something else bubbling with breakout potential!
This NYSE American profile is popping up on my radar for 2 immediate reasons:
#1. This is a low float profile with fewer than 14Mn shares in its float, which means volatility potential could be significant.
Could that be part of the reason as to why this profile was able to complete a 250% move during the past 12 month period?
#2. A game-changing February press release has somehow stayed off Wall Street's radar, but the details inside are eye-opening. In fact, the catalyst potential talked about in that PR could be monumental for the company.
As this company powers forward in 2025 and beyond, it may just be a matter of time until they become a household name as global health uncertainties could propel their game-changing work into the spotlight.
Hitting #1 on my watchlist this week, it may be time to consider this breakout idea for your radar: NanoViricides, Inc. (NYSE American: NNVC).
NanoViricides, Inc. is a global leader in the development of nanomedicine drugs.
Their unique nanoviricide® platform technology defines a novel mechanism enabling first-in class drugs against vir-uses.
A nanoviricide is designed to specifically attack enveloped vir-us particles, on the same sites that they use to bind to cells, and dismantle them, blocking reinfection cycle, going beyond what antibodies and immunotherapeutics do.
It can also be designed to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity.
The company's unique biomimetic approach enables creation of drugs that a vir-us would be highly unlikely to escape due to mutations.
NanoViricides is one of the few biopharma companies with its own multi-kilogram-scale c-GMP capable manufacturing facility for the drug substance as well as drug product.
This facility is fully owned by the Company with no mortgage and is a major asset.
This flexible, multi-product pilot plant can supply drug product for all of their programs through human clinical trials.
Their cGMP manufacturing ability enables substantial time and cost savings in their drug development programs.
Further, it is capable of production for initial marketing, enabling early revenues upon drug approval, of about $100Mn~$500Mn per year.
Company Sources: Presentation. Website. | 
No comments:
Post a Comment